Immunome Inc
NASDAQ:IMNM

Watchlist Manager
Immunome Inc Logo
Immunome Inc
NASDAQ:IMNM
Watchlist
Price: 8.76 USD -2.12% Market Closed
Market Cap: 762.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+23%
Revenue
Forecast
+6%
Operating Income
Forecast
+34%
Net Income
Forecast
-15%

Wall Street
Price Targets

IMNM Price Targets Summary
Immunome Inc

Wall Street analysts forecast IMNM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMNM is 24.14 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

IMNM Lowest Forecast
Wall Street Target
20.2 USD
131% Upside
IMNM Average Forecast
Wall Street Target
24.14 USD
176% Upside
IMNM Highest Forecast
Wall Street Target
31.5 USD
260% Upside
Lowest
Price Target
20.2 USD
131% Upside
Average
Price Target
24.14 USD
176% Upside
Highest
Price Target
31.5 USD
260% Upside
Immunome Inc Competitors:
Price Targets
OSE
OSE Immunotherapeutics SA
182% Upside
300685
Amoy Diagnostics Co Ltd
48% Upside
BSLN
Basilea Pharmaceutica AG
100% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
6% Upside
OSE
OSE Immunotherapeutics SA
182% Upside
300685
Amoy Diagnostics Co Ltd
48% Upside
BSLN
Basilea Pharmaceutica AG
100% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
6% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
11% Downside
002007
Hualan Biological Engineering Inc
21% Upside
S
4599
StemRIM Inc
120% Upside

Revenue
Forecast

Revenue Estimate
Immunome Inc

The compound annual growth rate of Immunome Inc's revenue for the next 3 years is 101%.

N/A
Past Growth
101%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Immunome Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Immunome Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-86%
Average Miss
What are analyst estimates?

See Also

Summary
IMNM intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMNM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMNM stock valuation using valuation multiples.
Wall Street Estimates
IMNM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMNM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IMNM's stock price target?
Price Target
24.14 USD

According to Wall Street analysts, the average 1-year price target for IMNM is 24.14 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

What is Immunome Inc's Revenue forecast?
Projected CAGR
101%

The compound annual growth rate of Immunome Inc's revenue for the next 3 years is 101%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.